{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:43:45Z","timestamp":1787010225964,"version":"build-2736575974"},"reference-count":66,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>The causal role of LDL in atherosclerotic cardiovascular disease (ASCVD) is well established, but the contribution of HDL has proven more complex. CETP inhibitors were originally developed to increase HDL-cholesterol (HDL-C), but the failure of clinical trials and genetic evidence have changed our understanding of CETP biology. With the development of obicetrapib, a next-generation CETP inhibitor, there has been renewed interest in its therapeutic potential. This review summarizes the latest findings on CETP inhibition and highlights the evolving perspectives from lipid modulation to broader clinical applications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Clinical trials and Mendelian randomisation consistently show that increasing HDL-C alone does not reduce cardiovascular risk, while lowering apoB-containing lipoproteins is associated with benefit. Off-target effects, modest efficacy or insufficient follow-up limited previous CETP inhibitors. Obicetrapib, in contrast, achieves a significant LDL-C and apoB reduction, a marked HDL-C increase and favourable safety. Beyond ASCVD, CETP inhibition may also have an impact on diabetes risk, cognitive function and possibly other conditions, although data are still preliminary.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>The therapeutic focus has shifted from HDL-C elevation to apoB lowering as the determinant of cardiovascular benefit. Obicetrapib shows promise, with ongoing trials designed to define its role in ASCVD management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mol.0000000000001017","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T13:00:26Z","timestamp":1762347626000},"page":"318-325","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["The two faces of cholesteryl ester transfer protein inhibitors"],"prefix":"10.1097","volume":"36","author":[{"given":"Angela","family":"Pirillo","sequence":"first","affiliation":[{"name":"Center for the Study of Atherosclerosis, E. Bassini Hospital, Cinisello Balsamo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[{"name":"Center for the Study of Atherosclerosis, IRCCS MultiMedica, Sesto San Giovanni"},{"name":"Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"R1-20251105","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"R2-20251105","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1093\/eurheartj\/ehac605","article-title":"High-density lipoprotein revisited: biological functions and clinical relevance","volume":"44","author":"von Eckardstein","year":"2023","journal-title":"Eur Heart J"},{"key":"R3-20251105","doi-asserted-by":"crossref","first-page":"777","DOI":"10.14348\/molcells.2014.0265","article-title":"Cholesteryl ester transfer protein (CETP) deficiency and CETP inhibitors","volume":"37","author":"Mabuchi","year":"2014","journal-title":"Mol Cells"},{"key":"R4-20251105","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1093\/eurheartj\/ehx163","article-title":"Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies","volume":"38","author":"Madsen","year":"2017","journal-title":"Eur Heart J"},{"key":"R5-20251105","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1093\/eurheartj\/ehx665","article-title":"U-shaped relationship of HDL and risk of infectious disease: two prospective population-based cohort studies","volume":"39","author":"Madsen","year":"2018","journal-title":"Eur Heart J"},{"key":"R6-20251105","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1093\/cvr\/cvab350","article-title":"Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?","volume":"118","author":"Nurmohamed","year":"2022","journal-title":"Cardiovasc Res"},{"key":"R7-20251105","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1194\/jlr.M300198-JLR200","article-title":"Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency","volume":"45","author":"Asztalos","year":"2004","journal-title":"J Lipid Res"},{"key":"R8-20251105","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1210\/jc.2005-2322","article-title":"An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study","volume":"91","author":"Borggreve","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R9-20251105","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0022-2275(20)33876-1","article-title":"Relationship of HDL and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia","volume":"39","author":"Bruce","year":"1998","journal-title":"J Lipid Res"},{"key":"R10-20251105","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1161\/01.CIR.101.16.1907","article-title":"Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene","volume":"101","author":"Agerholm-Larsen","year":"2000","journal-title":"Circulation"},{"key":"R11-20251105","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1001\/jamacardio.2017.4177","article-title":"Association of CETP gene variants with risk for vascular and nonvascular diseases among Chinese Adults","volume":"3","author":"Millwood","year":"2018","journal-title":"JAMA Cardiol"},{"key":"R12-20251105","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1161\/CIRCRESAHA.117.311145","article-title":"Protein-truncating variants at the cholesteryl ester transfer protein gene and risk for coronary heart disease","volume":"121","author":"Nomura","year":"2017","journal-title":"Circ Res"},{"key":"R13-20251105","doi-asserted-by":"crossref","first-page":"120417","DOI":"10.1016\/j.atherosclerosis.2025.120417","article-title":"Protein-truncating variants of the cholesteryl ester transfer protein gene and risk for coronary artery disease among patients with heterozygous familial hypercholesterolemia","volume":"408","author":"Tada","year":"2025","journal-title":"Atherosclerosis"},{"key":"R14-20251105","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jamacardio.2021.3728","article-title":"Long-term benefits and harms associated with genetic cholesteryl ester transfer protein deficiency in the general population","volume":"7","author":"Nordestgaard","year":"2022","journal-title":"JAMA Cardiol"},{"key":"R15-20251105","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/jama.2017.11467","article-title":"Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk","volume":"318","author":"Ference","year":"2017","journal-title":"JAMA"},{"key":"R16-20251105","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"R17-20251105","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"R18-20251105","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N Engl J Med"},{"key":"R19-20251105","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"HPS3\/TIMI55\u2013REVEAL Collaborative Group","year":"2017","journal-title":"N Engl J Med"},{"key":"R20-20251105","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jacc.2018.10.072","article-title":"Cholesteryl ester transfer protein inhibition for preventing cardiovascular events: JACC Review Topic of the Week","volume":"73","author":"Armitage","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R21-20251105","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/eurheartj\/ehab863","article-title":"Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease","volume":"43","author":"HPS3\/TIMI55-REVEAL Collaborative Group, Writing Committee","year":"2022","journal-title":"Eur Heart J"},{"key":"R22-20251105","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/cpt.700","article-title":"Chronic administration of anacetrapib is associated with accumulation in adipose and slow elimination","volume":"102","author":"Krishna","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"R23-20251105","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/MOL.0000000000000955","article-title":"Cholesteryl ester transfer protein inhibition: a pathway to reducing risk of morbidity and promoting longevity","volume":"35","author":"Davidson","year":"2024","journal-title":"Curr Opin Lipidol"},{"key":"R24-20251105","doi-asserted-by":"crossref","first-page":"1512670","DOI":"10.3389\/fendo.2025.1512670","article-title":"Lipid-lowering effect of combined therapy with high-intensity statins and CETP inhibitors: a systematic review and meta-analysis","volume":"16","author":"Xiang","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R25-20251105","doi-asserted-by":"crossref","first-page":"9417","DOI":"10.3390\/ijms23169417","article-title":"Cholesteryl ester transfer protein inhibition reduces major adverse cardiovascular events by lowering apolipoprotein B levels","volume":"23","author":"Nelson","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R26-20251105","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"key":"R27-20251105","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/eurheartj\/eht571","article-title":"Mendelian randomization of blood lipids for coronary heart disease","volume":"36","author":"Holmes","year":"2015","journal-title":"Eur Heart J"},{"key":"R28-20251105","doi-asserted-by":"crossref","first-page":"e1003062","DOI":"10.1371\/journal.pmed.1003062","article-title":"Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis","volume":"17","author":"Richardson","year":"2020","journal-title":"PLoS Med"},{"key":"R29-20251105","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1001\/jamacardio.2016.1884","article-title":"Association of lipid fractions with risks for coronary artery disease and diabetes","volume":"1","author":"White","year":"2016","journal-title":"JAMA Cardiol"},{"key":"R30-20251105","doi-asserted-by":"crossref","first-page":"zwaf554","DOI":"10.1093\/eurjpc\/zwaf554","article-title":"Apolipoprotein B outperforms low density lipoprotein particle number as a marker of cardiovascular risk in the UK Biobank","author":"Epstein","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"R31-20251105","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"key":"R32-20251105","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/bcp.12380","article-title":"Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects","volume":"78","author":"Ford","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"R33-20251105","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2025.07.003","article-title":"Obicetrapib and its impact on lipid parameters: a comprehensive meta-analysis of the latest evidence","author":"Bhatti","year":"2025","journal-title":"J Clin Lipidol"},{"key":"R34-20251105","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jacl.2024.12.016","article-title":"Lipid-lowering efficacy of obicetrapib: a comprehensive systematic review and meta-analysis","volume":"19","author":"Masson","year":"2025","journal-title":"J Clin Lipidol"},{"key":"R35-20251105","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMoa2415820","article-title":"Safety and efficacy of obicetrapib in patients at high cardiovascular risk","volume":"393","author":"Nicholls","year":"2025","journal-title":"N Engl J Med"},{"key":"R36-20251105","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0140-6736(15)60158-1","article-title":"Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"386","author":"Hovingh","year":"2015","journal-title":"Lancet"},{"key":"R37-20251105","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1038\/s41591-022-01936-7","article-title":"Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial","volume":"28","author":"Nicholls","year":"2022","journal-title":"Nat Med"},{"key":"R38-20251105","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40256-025-00740-1","article-title":"A drug-drug interaction study evaluating the pharmacokinetic consequences of obicetrapib therapy on atorvastatin or rosuvastatin levels in healthy volunteers","volume":"25","author":"Kastelein","year":"2025","journal-title":"Am J Cardiovasc Drugs"},{"key":"R39-20251105","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jacl.2023.05.098","article-title":"Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: a randomized phase 2 trial","volume":"17","author":"Ballantyne","year":"2023","journal-title":"J Clin Lipidol"},{"key":"R40-20251105","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(25)00721-4","article-title":"Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"405","author":"Sarraju","year":"2025","journal-title":"Lancet"},{"key":"R41-20251105","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11883-025-01276-0","article-title":"Highlights of cardiovascular disease prevention studies presented at the 2024 American Heart Association Scientific Sessions","volume":"27","author":"Hermel","year":"2025","journal-title":"Curr Atheroscler Rep"},{"key":"R42-20251105","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jacc.2025.07.056","article-title":"Impact of obicetrapib on major adverse cardiovascular events in high-risk patients: a pooled analysis","volume":"86","author":"Nicholls","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"R43-20251105","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ahj.2025.07.012","article-title":"Rationale and design of the REMBRANDT trial: a phase 3 study to evaluate the effect of obicetrapib\/ezetimibe on coronary plaque characteristics","volume":"290","author":"McCarthy","year":"2025","journal-title":"Am Heart J"},{"key":"R44-20251105","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.5551\/jat.64828","article-title":"Obicetrapib as an adjunct to stable statin therapy in Japanese subjects: results from a randomized phase 2 trial","volume":"31","author":"Harada-Shiba","year":"2024","journal-title":"J Atheroscler Thromb"},{"key":"R45-20251105","doi-asserted-by":"crossref","first-page":"117213","DOI":"10.1016\/j.atherosclerosis.2023.117213","article-title":"HDL abnormalities in type 2 diabetes: clinical implications","volume":"394","author":"Martagon","year":"2024","journal-title":"Atherosclerosis"},{"key":"R46-20251105","doi-asserted-by":"crossref","first-page":"106972","DOI":"10.1016\/j.phrs.2023.106972","article-title":"The evolving role of cholesteryl ester transfer protein inhibition beyond cardiovascular disease","volume":"197","author":"Mehta","year":"2023","journal-title":"Pharmacol Res"},{"key":"R47-20251105","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.1038\/s41467-021-25703-3","article-title":"Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease","volume":"12","author":"Schmidt","year":"2021","journal-title":"Nat Commun"},{"key":"R48-20251105","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/ehjcvp\/pvac025","article-title":"The effect of CETP inhibitors on new-onset diabetes: a systematic review and meta-analysis","volume":"8","author":"Dangas","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"R49-20251105","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1016\/j.jacl.2025.04.167","article-title":"Effect of obicetrapib on new onset diabetes in patients with elevated LDL-C receiving maximally tolerated statin therapy: pooled analyses of the Broadway and Brooklyn trials. Abstract presented at the 9th Annual Heart in Diabetes Conference in Philadelphia, PA, from June 6-8, 2025","volume":"19","author":"Ray","year":"2025","journal-title":"J Clin Lipidol"},{"key":"R50-20251105","doi-asserted-by":"crossref","first-page":"200.e7","DOI":"10.1016\/j.neurobiolaging.2016.02.006","article-title":"Cholesteryl ester transfer protein genotype modifies the effect of apolipoprotein epsilon4 on memory decline in older adults","volume":"41","author":"Sundermann","year":"2016","journal-title":"Neurobiol Aging"},{"key":"R51-20251105","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1001\/jama.2009.1988","article-title":"Association of a functional polymorphism in the cholesteryl ester transfer protein (CETP) gene with memory decline and incidence of dementia","volume":"303","author":"Sanders","year":"2010","journal-title":"JAMA"},{"key":"R52-20251105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2008.07.047","article-title":"CETP polymorphisms influence cholesterol metabolism but not Alzheimer's disease risk","volume":"1232","author":"Qureischie","year":"2008","journal-title":"Brain Res"},{"key":"R53-20251105","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10048-007-0089-x","article-title":"The cholesteryl ester transfer protein (CETP) gene and the risk of Alzheimer's disease","volume":"8","author":"Arias-Vasquez","year":"2007","journal-title":"Neurogenetics"},{"key":"R54-20251105","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11682-011-9137-0","article-title":"CETP polymorphisms associate with brain structure, atrophy rate, and Alzheimer's disease risk in an APOE-dependent manner","volume":"6","author":"Murphy","year":"2012","journal-title":"Brain Imaging Behav"},{"key":"R55-20251105","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.brainres.2007.10.054","article-title":"Cholesteryl ester transfer protein polymorphism D442G associated with a potential decreased risk for Alzheimer's disease as a modifier for APOE epsilon4 in Chinese","volume":"1187","author":"Chen","year":"2008","journal-title":"Brain Res"},{"key":"R56-20251105","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13195-024-01594-6","article-title":"Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis","volume":"16","author":"Schmidt","year":"2024","journal-title":"Alzheimers Res Ther"},{"key":"R57-20251105","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ophtha.2024.12.039","article-title":"High-density lipoproteins associated with age-related macular degeneration in the All of Us Research Program","volume":"132","author":"Chen","year":"2025","journal-title":"Ophthalmology"},{"key":"R58-20251105","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/ng.3448","article-title":"A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants","volume":"48","author":"Fritsche","year":"2016","journal-title":"Nat Genet"},{"key":"R59-20251105","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12920-020-00760-7","article-title":"Genome-wide association meta-analysis for early age-related macular degeneration highlights novel loci and insights for advanced disease","volume":"13","author":"Winkler","year":"2020","journal-title":"BMC Med Genomics"},{"key":"R60-20251105","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1038\/ncomms7063","article-title":"New loci and coding variants confer risk for age-related macular degeneration in East Asians","volume":"6","author":"Cheng","year":"2015","journal-title":"Nat Commun"},{"key":"R61-20251105","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.ophtha.2017.03.042","article-title":"Mendelian randomization implicates high-density lipoprotein cholesterol-associated mechanisms in etiology of age-related macular degeneration","volume":"124","author":"Burgess","year":"2017","journal-title":"Ophthalmology"},{"key":"R62-20251105","doi-asserted-by":"crossref","first-page":"15711","DOI":"10.1038\/srep15711","article-title":"CETP\/LPL\/LIPC gene polymorphisms and susceptibility to age-related macular degeneration","volume":"5","author":"Wang","year":"2015","journal-title":"Sci Rep"},{"key":"R63-20251105","doi-asserted-by":"crossref","first-page":"e031459","DOI":"10.1161\/JAHA.123.031459","article-title":"Genome-wide association study of cardiovascular resilience identifies protective variation in the CETP Gene","volume":"12","author":"Yu","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"R64-20251105","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"Bowman","year":"2017","journal-title":"N Engl J Med"},{"key":"R65-20251105","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/eurjpc\/zwae044","article-title":"Genetic association of lipid-lowering drugs with aortic aneurysms: a Mendelian randomization study","volume":"31","author":"Gao","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"R66-20251105","doi-asserted-by":"crossref","first-page":"292","DOI":"10.31083\/j.rcm2508292","article-title":"Causal relationships between lipid-lowering drug target and aortic disease and calcific aortic valve stenosis: a two-sample Mendelian Randomization","volume":"25","author":"Yang","year":"2024","journal-title":"Rev Cardiovasc Med"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000001017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T13:00:34Z","timestamp":1762347634000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000001017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":66,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0000000000001017","relation":{},"ISSN":["0957-9672","1473-6535"],"issn-type":[{"value":"0957-9672","type":"print"},{"value":"1473-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]}}}